Optimizing the Evaluation and Management of Patients With Suspected Choledocholithiasis
Launched by UNIVERSITY OF CALGARY · Nov 19, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best ways to evaluate and manage patients who may have choledocholithiasis, which means stones in the common bile duct. This condition can lead to serious health problems if it's not treated properly. The trial is looking at different methods for diagnosing and deciding on treatment for patients who are suspected of having these stones, especially those who fall into an "intermediate risk" category. This group currently has limited options, often leading them to undergo a procedure called endoscopic retrograde cholangiopancreatography (ERCP), which is effective but comes with risks. Researchers are exploring whether looking at changes in liver enzymes could help improve the evaluation process for these patients.
To participate in this trial, individuals must be at least 18 years old and have suspected choledocholithiasis. They must also be able to give informed consent, meaning they understand what the trial involves. Those who have had previous treatments for choledocholithiasis or have certain other health conditions may not be eligible. Participants can expect to undergo additional tests that can help doctors better understand their condition and decide on the safest and most effective treatment. This research aims to improve the way doctors assess and treat patients with suspected bile duct stones, ultimately leading to better health outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with suspected choledocholithiasis, regardless of probability
- • age 18 years old or older
- • able to give informed consent to involvement (in the prospective validation phase).
- Exclusion Criteria:
- • Unable or unwilling to provide informed consent;
- • age \< 18 years;
- • suspected or proven cholangitis;
- • previous ERCP with sphincterotomy;
- • prior diagnosis or management of choledocholithiasis;
- • outpatient status;
- • out-of-province status (prohibiting full medical record access).
About University Of Calgary
The University of Calgary is a leading research institution dedicated to advancing health and science through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university's clinical research initiatives aim to address pressing health challenges and improve patient outcomes. The institution fosters a robust environment for academic inquiry, leveraging state-of-the-art facilities and a diverse network of experts in various fields. Committed to ethical research practices and community engagement, the University of Calgary strives to translate scientific discoveries into tangible benefits for society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Calgary, Alberta, Canada
Patients applied
Trial Officials
Nauzer Forbes, MD, MSc
Principal Investigator
University of Calgary
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials